MedDataX Logo

The Efficacy in Treatment of Female Pattern Hair Loss Using 5% Minoxidil Solution Combinded With Zinc Supplement

NCT ID: NCT01662089

Last Updated: 2012-08-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1/PHASE2

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Zinc supplement is a popular trace element gave to Female pattern hair loss (FPHL) patient. But the type of patient, efficacy, and side effect in detail of zinc supplement are not well characterized. The purpose of this study is to determine efficacy and side effect of chelated zinc in FPHL who using 5%minoxidil solution.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

5%minoxidil solution is standard treatment for Female pattern hair loss (FPHL) patient. We gave 15mg chelate Zinc / Placebo drug to patient as an additional trace element. Then measure growth of hair by Global photograph, Microscope hair count, micrometer and record case and side effect during 10 months of treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Female Pattern Alopecia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Female pattern hair loss

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Chelate zinc suppliment

15mg Chelate zinc suppliment : additional to standard 5% minoxidil

Group Type EXPERIMENTAL

15 mg Chelate zinc supplement

Intervention Type DRUG

15 mg Chelate zinc additional to standard 5% minoxidil

Placebo drug

Placebo drug to compare with 15mg chelated Zn : additional to standard 5% minoxidil

Group Type PLACEBO_COMPARATOR

Placebo drug supplement

Intervention Type DRUG

Placebo drug instead of Zinc supplement

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

15 mg Chelate zinc supplement

15 mg Chelate zinc additional to standard 5% minoxidil

Intervention Type DRUG

Placebo drug supplement

Placebo drug instead of Zinc supplement

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

zinc, Zn starch

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female Pattern Hair Loss ( Ludwig classification grade 1 and 2 )

Exclusion Criteria

* Underlying disease ; Anemia, Diabetes, chronic alcoholism, previous gastrointestinal surgery, short bowel syndrome, Crohn's disease, digestive disorder, hypo/hyperthyroidism, sickle cell disease, autoimmune disease, iron deficiency
* Psychologic disorder trichotillomania
* Diet control
* Pregnancy or lactation
* On supplement diet within 3 month prior to trial
Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Siriraj Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Rattapon Thuangtong

Associate Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Siriraj Hospital

Bangkok, , Thailand

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rattapon Thuangtong, MD

Role: CONTACT

Phone: +662 419-7000

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Rattapon Thuangtong, MD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SirirajH-004

Identifier Type: -

Identifier Source: org_study_id